ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-B7-H3 Antibody-drug Conjugate MHB088C

Its studies are mostly in Small Cell Lung Carcinoma, led by 2 companies.

Drug pageAnti-B7-H3 Antibody-drug Conjugate MHB088C: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 30, 20224 company-led studies, 4 open or runningNext primary completion: May 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Minghui Pharmaceutical22 open or runningphase 2since Nov 30, 2022Nov 30, 2022Aug 2029phase 2 · NCT07126665
Qilu Pharmaceuticalits history only22 open or runningphase 3since Apr 18, 2025Apr 18, 2025May 2027phase 3 · NCT06954246

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Minghui Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 30, 2022First study: phase 2 study in Advanced or Metastatic Solid TumorsFirst studyNCT05652855 · 48 planned · Australia
  2. Aug 11, 2025Phase 2 study in Advanced Malignant Solid TumorNCT07126665 · 116 planned · China

Ahead

  1. Aug 2029Primary completion: phase 2 study in Advanced Malignant Solid TumorNCT07126665

TargetBeta

CD276 →read by rule
“An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) ”NCIt, by rule

Other programs on CD276

ProgramCompanyFurthest phaseStudies
risvutatug rezetecanHansoh Pharmaceutical Groupphase 330
ifinatamab deruxtecanMerckphase 316
tambotatug pelitecanMediLink Therapeutics (Suzhou)phase 313
Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043CSPC Pharmaceutical Groupphase 36
Elfetabart DrozuntecanruleBioNTechphase 33
Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101ruletj-biopharma-co-ltdphase 33
Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01ruleradiopharm-theranostics-ltdphase 21
Autologous Anti-B7-H3 CAR T-cells BCB-276rulebrainchild-bio-incphase 21
Anti-B7-H3/CD28 Bispecific Antibody XmAb808ruleXencorphase 12
Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034ruleideaya-biosciencesphase 11
Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001ruleneok-bio-incphase 11
HLX316Fosun Pharmaphase 11

Studies

All 2 Minghui Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07126665Advanced Malignant Solid Tumor · China2RecruitingAug 2029116
NCT05652855Advanced or Metastatic Solid Tumors · Australia2Not yet recruitingJan 31, 202648

How it is read

Names in the registry

  • “MHB088C for Injection”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.